期刊文献+

葛兰素史克公司对美国糖尿病学会和欧洲糖尿病研究学会共识声明的回应

原文传递
导出
摘要 致编辑:葛兰素史克对最近美国糖尿病学会和欧洲糖尿病研究学会共识声明中不推荐2型糖尿病使用罗格列酮治疗的建议…表示遗憾,因为这有悖于科学证据。
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2009年第2期I0009-I0009,共1页 Chinese Journal of Endocrinology and Metabolism
  • 相关文献

参考文献7

  • 1Nathan D, Buse J, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia,2009, 52 : 17-30.
  • 2Kahn SE, Haffner S, Heise MA, et al. Glycemic durability of rosiglitazone, mefformin, or glyburide monotherapy. N Engl J Med, 2006, 355:2427-2443.
  • 3Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med,2007, 357:28-38.
  • 4Nathan DM. Glycemic management of type 2 diabetes : how tight is right and how to get there. Arch Intern Med ,2008,168:2064-2066.
  • 5Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trims. Lancet ,2007, 370 : 1129-1136.
  • 6US Food and Drug Administration (2007) FDA briefing document. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, July 30, 2007. Available from www. fda. gov/ohrms/dockets/ac/07/briefing/2007-4308bl-02-fda-backgrounder. pdf, accessed 9 January 2009.
  • 7Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care,2008, 31:1672-1678.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部